- References (1)
- Inventor Info
|Antigen/Gene or Protein Targets||Trh4 Db KO|
|Disease Keywords||Mouse Leukemia|
|Relevance||This cell line overexpresses the ER-resident ceramide synthase Trh4 (transduced by CRISPR) and lacks the H2-Db gene. It serves as a control in helping to understanding T-cell recognition of the Trh4-derived peptide presented by the MHC class I molecule H2-Db. This peptide-epitope is a prototypic example of a neo‐antigen selectively presented by cells with processing defects in the classical MHC class I (MHC‐I) pathway. RMA cells have an intact processing pathway and a functional TAP peptide transporter, but overexpress the Trh4 protein and therefore could present the Trh4 peptide. However, no T cell recognition can be observed due to the absence of the MHC class I H2-Db.This population acts as a clear control.|
|Production Details||Retroviral transduction of the mouse Trh4 gene in an IRES-GFP construct and CRISPR/Cas9 technology|
|Recommended Growing Conditions||Suspension cells in DMEM+8% FCS|
|Positive Control||RMA.Trh4 Kb KO cells|
CRISPR edited RMA cells.
Cancer Research Technology Limited (trading research tools as Ximbio) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here.
This license from ERS Genomics Ltd allows Ximbio to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. Ximbio can provide these modified CRISPR-Cas9 cell lines to companies under a label-use only license.
There are 1 reference entries for this reagent.View All References
Thorbald Van Hall